Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

61. Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline. Full Text available with Trip Pro

Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline. The Kidney Disease: Improving Global Outcomes (KDIGO) 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is an extensive update of KDIGO's 2008 guideline on HCV infection in CKD. This update

2019 Annals of Internal Medicine

62. Impact of chronic kidney disease on outcomes after total joint arthroplasty: A meta-analysis & systematic review. Full Text available with Trip Pro

Impact of chronic kidney disease on outcomes after total joint arthroplasty: A meta-analysis & systematic review. Impact of chronic kidney disease on outcomes after total joint arthroplasty: A meta-analysis & systematic review. | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint (...) on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Impact of chronic kidney disease on outcomes after total joint arthroplasty: A meta-analysis & systematic review. Jiang Chen, Fan Zhang, Chu-Yin Liu, Qiao-Mei Yuan, Xue-Shi Di, Shui-Wen Long, Hong-Cai Shang, Yu-Song Jia Jiang Chen Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital Fan Zhang Beijing

2019 Research Square

63. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Full Text available with Trip Pro

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Spironolactone is effective at reducing blood pressure in patients with uncontrolled resistant hypertension. However, the use of spironolactone in patients with chronic kidney disease can be restricted by hyperkalaemia. We evaluated use of the potassium binder patiromer to allow more persistent use (...) of spironolactone in patients with chronic kidney disease and resistant hypertension.In this phase 2 multicentre, randomised, double-blind, placebo-controlled study, we enrolled participants aged 18 years and older with chronic kidney disease (estimated glomerular filtration rate 25 to ≤45 mL/min per 1·73 m2) and uncontrolled resistant hypertension from 62 outpatient centres in ten countries (Bulgaria, Croatia, Georgia, Hungary, Ukraine, France, Germany, South Africa, the UK, and the USA). Patients meeting all

2019 Lancet

64. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Full Text available with Trip Pro

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention).In CREDENCE (Canagliflozin and Renal Events in Diabetes (...) ]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (P for interaction >0.5 for each outcome).Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease.URL: https

2019 EvidenceUpdates

65. eHealth interventions for people with chronic kidney disease. Full Text available with Trip Pro

eHealth interventions for people with chronic kidney disease. Chronic kidney disease (CKD) is associated with high morbidity and death, which increases as CKD progresses to end-stage kidney disease (ESKD). There has been increasing interest in developing innovative, effective and cost-efficient methods to engage with patient populations and improve health behaviours and outcomes. Worldwide there has been a tremendous increase in the use of technologies, with increasing interest in using eHealth (...) interventions to improve patient access to relevant health information, enhance the quality of healthcare and encourage the adoption of healthy behaviours.This review aims to evaluate the benefits and harms of using eHealth interventions to change health behaviours in people with CKD.We searched the Cochrane Kidney and Transplant Register of Studies up to 14 January 2019 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through

2019 Cochrane

66. Chronic renal diseases and pregnancy

.” International Journal of Women’s Health 8 (July): 273–85. Gonzalez Suarez, Maria L., Andrea Kattah, Joseph P. Grande, and Vesna Garovic. 2018. “Renal Disorders in Pregnancy: Core Curriculum 2019.” American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, August. https://doi.org/10.1053/j.ajkd.2018.06.006. Hladunewich, Michelle A. 2017. “Chronic Kidney Disease and Pregnancy.” Seminars in Nephrology 37 (4): 337–46. Imbasciati, Enrico, Gina Gregorini, Gianfranca Cabiddu (...) in English (4 pages) 2. Entire guideline in Danish (35 pages) Summary of clinical recommendations: Chronic Kidney Disease and pregnancy: CKD Recommendations Level of evidence Recommendation Preconception Counselling in cooperation with a nephrologist and an obstetrician with special interest in nephrology A Level of renal impairment, presence of hypertension and proteinuria are the strongest prognostics for the outcome of the pregnancy as well as the risk of progression of renal disease /progression

2019 Nordic Federation of Societies of Obstetrics and Gynecology

67. Tolvaptan (Jinarc ) for the treatment of chronic kidney disease - alteration of the specific conditions

Tolvaptan (Jinarc ) for the treatment of chronic kidney disease - alteration of the specific conditions Tolvaptan (Jinarc ®) for the treatment of chronic kidney disease - alteration of the specific conditions | Report | National Health Care Institute You are here: Tolvaptan (Jinarc ®) for the treatment of chronic kidney disease - alteration of the specific conditions Search within English part of National Health Care Institute Search Tolvaptan (Jinarc ®) for the treatment of chronic kidney (...) supportive care for ADPKD patients with chronic kidney disease (CKD) stages 1 to 3. For the effectiveness of tolvaptan in patients with CKD stage 3b, the evidence was scant. As a result, reimbursement is currently possible based on the following condition: Only for an insured person aged 18 years and older with autosomal dominant polycystic kidney disease (ADPKD) with chronic kidney disease (CKD) in stages 1 to 3a at the start of the treatment, with evidence of rapidly progressing disease, and in line

2019 National Health Care Institute (Zorginstituut Nederland)

68. Dialysate temperature reduction for intradialytic hypotension for people with chronic kidney disease requiring haemodialysis. Full Text available with Trip Pro

Dialysate temperature reduction for intradialytic hypotension for people with chronic kidney disease requiring haemodialysis. Intradialytic hypotension (IDH) is a common complication of haemodialysis (HD), and a risk factor of cardiovascular morbidity and death. Several clinical studies suggested that reduction of dialysate temperature, such as fixed reduction of dialysate temperature or isothermal dialysate using a biofeedback system, might improve the IDH rate.This review aimed to evaluate (...) the benefits and harms of dialysate temperature reduction for IDH among patients with chronic kidney disease requiring HD, compared with standard dialysate temperature.We searched Cochrane Kidney and Transplant's Specialised Register up to 14 May 2019 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search

2019 Cochrane

69. SUN-258 ASSOCIATION BETWEEN AIR POLLUANTS AND GLOBAL BURDEN OF DISEASE IN CHRONIC KIDNEY DISEASE: A SYSTEMIC REVIEW AND META-ANALYSIS Full Text available with Trip Pro

SUN-258 ASSOCIATION BETWEEN AIR POLLUANTS AND GLOBAL BURDEN OF DISEASE IN CHRONIC KIDNEY DISEASE: A SYSTEMIC REVIEW AND META-ANALYSIS Redirecting

2019 Kidney international reports

70. SAT-233 BEHAVIOR CHANGE TECHNIQUES IN LIFESTYLE INTERVENTIONS FOR PREVENTING THE PROGRESSION OF CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW Full Text available with Trip Pro

SAT-233 BEHAVIOR CHANGE TECHNIQUES IN LIFESTYLE INTERVENTIONS FOR PREVENTING THE PROGRESSION OF CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW Redirecting

2019 Kidney international reports

71. SUN-220 GENDER DIFFERENCES IN THE TREATMENT OF ADULTS WITH ADVANCED CHRONIC KIDNEY DISEASE COMMENCING RENAL REPLACEMENT THERAPY: A SYSTEMATIC REVIEW Full Text available with Trip Pro

SUN-220 GENDER DIFFERENCES IN THE TREATMENT OF ADULTS WITH ADVANCED CHRONIC KIDNEY DISEASE COMMENCING RENAL REPLACEMENT THERAPY: A SYSTEMATIC REVIEW Redirecting

2019 Kidney international reports

72. SUN-240 EFFECT OF EXERCISE TRAINING ON CARDIOVASCULAR AND KIDNEY OUTCOMES IN CHRONIC KIDNEY DISEASE PATIENTS: AN OVERVIEW OF SYSTEMATIC REVIEWS Full Text available with Trip Pro

SUN-240 EFFECT OF EXERCISE TRAINING ON CARDIOVASCULAR AND KIDNEY OUTCOMES IN CHRONIC KIDNEY DISEASE PATIENTS: AN OVERVIEW OF SYSTEMATIC REVIEWS Redirecting

2019 Kidney international reports

73. SUN-292 BENEFITS AND HARMS OF VITAMIN D COMPOUNDS IN ADULTS WITH CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS Full Text available with Trip Pro

SUN-292 BENEFITS AND HARMS OF VITAMIN D COMPOUNDS IN ADULTS WITH CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS Redirecting

2019 Kidney international reports

75. SAT-200 CAN PARATHYROID HORMONE ASSAY OR BEDSIDE ULTRASOUND IN THE PRIMARY CARE SETTING DIFFERENTIATE ACUTE KIDNEY INJURY FROM CHRONIC KIDNEY DISEASE? A SYSTEMATIC REVIEW Full Text available with Trip Pro

SAT-200 CAN PARATHYROID HORMONE ASSAY OR BEDSIDE ULTRASOUND IN THE PRIMARY CARE SETTING DIFFERENTIATE ACUTE KIDNEY INJURY FROM CHRONIC KIDNEY DISEASE? A SYSTEMATIC REVIEW Redirecting

2019 Kidney international reports

78. Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension. (Abstract)

Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension. Metabolic acidosis, a complication of chronic kidney disease, causes protein catabolism and bone demineralisation and is associated with adverse kidney outcomes and mortality. Veverimer, a non-absorbed, counterion-free, polymeric drug candidate selectively binds and removes hydrochloric acid from the gastrointestinal (...) lumen.We did a multicentre, randomised, blinded, placebo-controlled, 40-week extension of a 12-week parent study at 29 sites (hospitals and specialty clinics) in seven countries (Bulgaria, Georgia, Hungary, Serbia, Slovenia, Ukraine, and the USA). Eligible patients were those with chronic kidney disease (estimated glomerular filtration rate 20-40 mL/min per 1·73 m2) and metabolic acidosis (serum bicarbonate 12-20 mmol/L), who had completed the 12-week parent study, for which they were randomly assigned

2019 Lancet Controlled trial quality: predicted high

79. Use of Peripherally Inserted Central Catheters in Patients With Advanced Chronic Kidney Disease: A Prospective Cohort Study. (Abstract)

Use of Peripherally Inserted Central Catheters in Patients With Advanced Chronic Kidney Disease: A Prospective Cohort Study. Existing guidelines, including Choosing Wisely recommendations, endorse avoiding placement of peripherally inserted central catheters (PICCs) in patients with chronic kidney disease (CKD).To describe the frequency of and characteristics associated with PICC use in hospitalized patients with stage 3b or greater CKD (glomerular filtration rate [GFR] <45 mL/min/1.73 m2

2019 Annals of Internal Medicine

80. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, plac Full Text available with Trip Pro

Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, plac In patients with type 2 diabetes, intensive glucose control can be renoprotective and albuminuria-lowering treatments can slow the deterioration of kidney function. We assessed the albuminuria-lowering effect of the sodium-glucose co (...) groups. There were no new drug-related safety signals.Dapagliflozin with or without saxagliptin, given in addition to angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment, is a potentially attractive option to slow the progression of kidney disease in patients with type 2 diabetes and moderate-to-severe chronic kidney disease.AstraZeneca.Copyright © 2019 Elsevier Ltd. All rights reserved.

2019 EvidenceUpdates